FY2026 · ended Jun 30, 2026 · Revenue $57.57M, -13.3% YoY · Filed Sep 22, 2026
Aytu Biopharma, Inc. (AYTU) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Jun 30, 2026, it reported revenue of $57.6 million and a net loss of $14.3 million. Free cash flow was $3.3 million. As of Jun 30, 2026 it held $26.3 million in cash and investments and $12.0 million in total debt.
Revenue
$57.57M
-13.3% vs prior year
Net income
$-14.25M
-5.1% vs prior year
Operating cash flow
$3.28M
+269.4% vs prior year
Free cash flow
$3.25M
+250.2% vs prior year
EPS
$-5.11
+93.1% vs prior year
Dividend per share
None
Shares outstanding
10.87M
+9.6% vs prior year
Net cash
$14.28M
FY 2026
Operating margin
-14.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AYTU (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Denver, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1385818
- Former names
- AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $57.6M | $66.4M | $65.2M | $107.4M | $96.7M |
| Operating income | -$8.3M | -$7.8M | -$1.6M | -$17.1M | -$109.9M |
| Net income | -$14.3M | -$13.6M | -$15.8M | -$17.1M | -$108.8M |
| Diluted EPS | — | — | — | -$5.11 | -$74.01 |
| Operating cash flow | $3.3M | -$1.9M | -$1.4M | -$5.1M | -$28.8M |
| Free cash flow | $3.3M | -$2.2M | — | — | -$28.8M |
| Total assets | $105.0M | $124.2M | $118.1M | $136.5M | $137.6M |
| Total liabilities | — | — | — | $97.1M | $93.3M |
| Stockholders' equity | $35.3M | $19.0M | $27.7M | $39.4M | $44.3M |
| Cash and investments | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M |
| Total debt | $12.0M | $13.9M | $16.4M | $18.7M | $18.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Sep 22, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K |
Current report
Agreement ended
|
Jun 25, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Unregistered share sale, Change to shareholder rights
|
Apr 2, 2026 | Mar 31, 2026 |
All 907 Aytu Biopharma, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.